Literature DB >> 36199531

Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer.

Quan Jiang1,2,3, Chenyu Tian1,2,3, Hao Wu4, Lingqiang Min1,2,3, Hao Chen1,2,3, Lingli Chen5, Fenglin Liu1,2,3, Yihong Sun1,2,3.   

Abstract

Objective: Recent studies have highlighted the distinct value of tertiary lymphoid structure (TLS) for immunotherapeutic response prediction. However, it remains unclear whether TLS could play such roles in gastric cancer (GC).
Methods: In this study, tumor tissue slices from 292 GC patients from Zhongshan Hospital were firstly reviewed to explore the correlation between TLS and clinical characteristics. Subsequently, we curated 38 reported genes that may function as triggers of TLS and performed consensus molecular subtyping in public RNA-seq datasets to determine TLS patterns in GC. Based on the differentially expressed genes acquired from two TLS patterns, we quantified TLS-related genes on the principal component analysis (PCA) algorithm to develop TLS score. A Zhongshan immunotherapy cohort including 13 patients who received programmed cell death 1 (PD1) blockade therapy was established to conduct RNA sequencing analysis and multiplex immunohistochemistry (mIHC) tests using formalin-fixed and paraffin-embedded (FFPE) tissues. The corresponding TLS score and immune cell counts were further compared based on therapeutic response variations.
Results: Mature TLS was revealed as an independent prognostic factor in 292 GC patients. Patients with higher TLS score was characterized by prolonged survival time and superior response to immunotherapy. TLS score was correlated with immunotherapy-related characters, such as microsatellite instability (MSI) and tumor mutation burden (TMB). In addition, RNA-seq data analysis in the Zhongshan immunotherapy cohort indicated that a higher TLS score was correlated with a superior response to PD1 blockade therapy. mIHC tests also revealed that PD1+CD8+ T cell counts were significantly increased in the high-TLS score group. Conclusions: This study highlighted that TLS was significantly associated with immune landscape diversity and complexity. Quantitatively evaluating TLS patterns of individual tumor will strengthen our understanding of TME characteristics and promote more effective immunotherapy strategies. © Chinese Journal of Cancer Research. All rights reserved.

Entities:  

Keywords:  Gastric cancer; immune landscape; immunotherapy; tertiary lymphoid structures

Year:  2022        PMID: 36199531      PMCID: PMC9468020          DOI: 10.21147/j.issn.1000-9604.2022.04.05

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   4.026


  49 in total

1.  Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Authors:  Julien Calderaro; Florent Petitprez; Etienne Becht; Alexis Laurent; Théo Z Hirsch; Benoit Rousseau; Alain Luciani; Giuliana Amaddeo; Jonathan Derman; Cécile Charpy; Jessica Zucman-Rossi; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  J Hepatol       Date:  2018-09-11       Impact factor: 25.083

Review 2.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

3.  m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.

Authors:  Jianyang Du; Hang Ji; Shuai Ma; Jiaqi Jin; Shan Mi; Kuiyuan Hou; Jiawei Dong; Fang Wang; Chaochao Zhang; Yuan Li; Shaoshan Hu
Journal:  Brief Bioinform       Date:  2021-02-17       Impact factor: 11.622

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

Review 5.  B cells and cancer.

Authors:  Victor Engelhard; Jose R Conejo-Garcia; Rafi Ahmed; Brad H Nelson; Karen Willard-Gallo; Tullia C Bruno; Wolf H Fridman
Journal:  Cancer Cell       Date:  2021-09-30       Impact factor: 31.743

Review 6.  Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies.

Authors:  Hua Zhao; Hao Wang; Qiuru Zhou; Xiubao Ren
Journal:  Cancer Biol Med       Date:  2021-09-24       Impact factor: 5.347

7.  Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A large-scale cohort study.

Authors:  Ya-Qin Wang; Yu-Pei Chen; Yu Zhang; Wei Jiang; Na Liu; Jing-Ping Yun; Ying Sun; Qing-Mei He; Xin-Ran Tang; Xin Wen; Xiao-Jing Yang; Pan-Pan Zhang; Jian Zhang; Yuan Lei; Ying-Qin Li; Jun Ma
Journal:  Int J Cancer       Date:  2018-02-09       Impact factor: 7.396

8.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.

Authors:  Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu
Journal:  Nat Med       Date:  2018-08-20       Impact factor: 53.440

9.  m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer.

Authors:  Wei Chong; Liang Shang; Jin Liu; Zhen Fang; Fengying Du; Hao Wu; Yang Liu; Zhe Wang; Yang Chen; Shengtao Jia; Liming Chen; Leping Li; Hao Chen
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

10.  Prognostic Value of Tumor-Infiltrating Lymphocytes and Tertiary Lymphoid Structures in Epstein-Barr Virus-Associated and -Negative Gastric Carcinoma.

Authors:  Na Cheng; Peng Li; Huanhuan Cheng; Xiaoxiao Zhao; Min Dong; Yiwang Zhang; Peizhen Zhao; Jianning Chen; Chunkui Shao
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.